435P Cisplatin versus mitomycin plus fluoropyrimidine and radiation for localized squamous cell carcinoma of the anus (SCCA): Final results of GTG-LACOG 1318 real-world data study

01/09/2022

R.S.P. Riechelmann, A. Kruschewsky Coutinho Araujo, G. dos Santos Fernandes, R. Weschenfelder, D.R.D. Rocha Filho, L.A. Schlittler, J.F.D.M. Rego, G. Prolla, R.G. de Jesus, G.C.D.L. Gössling, R. D’Alpino Peixoto

DOI: 10.1016/j.annonc.2022.07.573

Full link: https://www.annalsofoncology.org/article/S0923-7534(22)02424-3/fulltext

435P Cisplatin versus mitomycin plus fluoropyrimidine and radiation for localized squamous cell carcinoma of the anus (SCCA): Final results of GTG-LACOG 1318 real-world data study

Send us a message

Cura Project

435P Cisplatin versus mitomycin plus fluoropyrimidine and radiation for localized squamous cell carcinoma of the anus (SCCA): Final results of GTG-LACOG 1318 real-world data study

Related Posts

In reply to Li et al. Letter to the editor. “Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials.”

Moderately hypofractionated post-operative radiation therapy for breast cancer: Preferences amongst radiation oncologists from countries in Latin America and the Caribbean

TP040/#1418 Palbociclib plus letrozole combination after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube or peritoneal cancer (LACOG 1018

Subgroup analysis of Brazilian participants of a medical leadership competencies instrument: a cross-sectional survey study of the Latin American Cooperative Oncology Group (LACOG) and the Academy of Leadership Sciences Switzerland (ALSS)